Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

ent. 

About Evolocumab (AMG 145)
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.2 Evolocumab, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 binding to LDL receptors on the liver's surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.1

Amgen has obtained the issuance of two U.S. patents related to evolocumab: USP 8,030,457 and USP 8,563,698. These patents will expire in 2029 but some extension period may be available, subject to certain regulatory conditions and statutory provisions for patent term extension.  

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large and comprehensive clinical trial program evaluating evolocumab. Phase 3 clinical trials for evolocumab are currently underway and build upon the Phase 2 studies.

The Phase 3 program includes 13 trials, with a combined planned enrollment of more than 28,000 patients. The Phase 3 studies will evaluate evolocumab administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with hyperlipidemia (LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.

Five s
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... for a number of breakthroughs, which altered the course ... paper, which laid the foundation of computer science, providing ... next played a pivotal role in the Second World ... codes, enabling the Allies to defeat the Nazis in ... turned his attention to artificial intelligence and proposed a ...
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Seed Grant awardee today with $25,000 to fund ... the Foundation,s inception in 2011, the gift was ... 11 th Annual Meeting in ... physicians who specialize in neurointerventional approaches to neurovascular ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 North Shore Towers, ... City, partnered with GI Energy, one of the nation’s leading ... $13 million upgrade of its 43-year-old CHP system. The original ... in an effort to extend the life of the plant, ... and associated electrical and heat recovery equipment, while maintaining continuous ...
(Date:7/31/2014)... 31, 2014 Senomyx , Inc. ... using proprietary taste science technologies to discover, develop, ... beverage, and ingredient supply industries, today reported financial ... ended the second quarter with $33.6 million in ... "During the past quarter Senomyx achieved another important ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... in German . , A mystical glow ... of nowhere. And a light source is invisible at ... source of the apparently supernatural illumination become visible: a light ... lens structures measuring only a few hundred nanometers, et voil: ...
... ... their complexity and substantial potential benefits for sponsors and patients. In Medelis, new issue ... of the adaptive trial model and the latest thinking about its application in phase I ... ...
... , AMSTERDAM ... today,announced that it has signed two commercial manufacturing agreements with ... process validation and GMP commercial manufacturing services to,support the commercial ... SynCo has commenced with preparations for ...
Cached Biology Technology:Nano for the senses 2Nano for the senses 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 2Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 4SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production 2
(Date:8/1/2014)... the fossil record about 200,000 years ago, but it ... and advanced tools became widespread. , A new ... Anthropology finds that human skulls changed in ways ... the same time that culture was blossoming. , "The ... rapid cultural exchange probably came at the same time ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
(Date:8/1/2014)... a more effective way to control the condition, thanks ... National University of Singapore (NUS). , The team, led ... Pharmacology at the NUS Yong Loo Lin School of ... PhD graduate from the Saw Swee Hock School of ... herbal-based anti-malarial drug, can be used to control asthma, ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2
... drinks during team sports could help young people perform better, ... olds can play for longer in team games when they ... Researchers at the University of Edinburgh measured the performance ... demands of team games such as football, rugby and hockey. ...
... structural analysis, scientists at the Carnegie Institution,s Department of ... 192 square miles in the African savanna. They found ... and landscape patterns associated with annual rainfall. The results ... how termite mounds can be used to predict ecological ...
... New Rochelle, NY, September 7, 2010Publisher Mary ... Obesity to provide physicians, nurses, dietitians, diabetes ... organizers, and policymakers with effective prevention and treatment ... education and motivation tools, and clinical advances in ...
Cached Biology News:Energy drinks may give young sports teams an edge, study says 2Termites foretell climate change in Africa's savannas 2Premier issue of new Childhood Obesity journal launched by Mary Ann Liebert Inc., publishers 2Premier issue of new Childhood Obesity journal launched by Mary Ann Liebert Inc., publishers 3
...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
... for cell culture scale-up, these culture chambers ... - 10 9 range and are ... spinner flasks. • High mechanical • strength ... prior to shipping • Certified nonpyrogenic and ...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
Biology Products: